About NeuroDerm
NeuroDerm is a company based in Ness Ziona (Israel) founded in 2003 was acquired by Mitsubishi Tanabe Pharma in July 2017.. NeuroDerm has raised $2.5 million across 6 funding rounds from investors including The Michael J. Fox Foundation and Mitsubishi Tanabe Pharma. NeuroDerm offers products and services including ND0612. NeuroDerm operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter Ness Ziona, Israel
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$2.5 M (USD)
in 6 rounds
-
Latest Funding Round
$1 M (USD), Grant
Jun 03, 2013
-
Investors
The Michael J. Fox Foundation
& 1 more
-
Employee Count
Employee Count
-
Acquired by
Mitsubishi Tanabe Pharma
(Jul 24, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NeuroDerm
NeuroDerm offers a comprehensive portfolio of products and services, including ND0612. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides continuous subcutaneous treatment for Parkinson's motor fluctuations.
Funding Insights of NeuroDerm
NeuroDerm has successfully raised a total of $2.5M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $1 million completed in June 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Grant — $1.0M
-
First Round
First Round
(12 May 2006)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2013 | Amount | Grant - NeuroDerm | Valuation |
investors |
|
| Oct, 2010 | Amount | Grant - NeuroDerm | Valuation |
investors |
|
| Aug, 2009 | Amount | Grant - NeuroDerm | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in NeuroDerm
NeuroDerm has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include The Michael J. Fox Foundation and Mitsubishi Tanabe Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Research for Parkinson's disease is funded by the foundation.
|
Founded Year | Domain | Location | |
|
Innovative therapies and drugs are developed by the pharmaceutical company.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by NeuroDerm
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - NeuroDerm
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Neuroderm Comparisons
Competitors of NeuroDerm
NeuroDerm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Drugs for CNS disorders are developed and advanced.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Neuroderm
Frequently Asked Questions about NeuroDerm
When was NeuroDerm founded?
NeuroDerm was founded in 2003 and raised its 1st funding round 3 years after it was founded.
Where is NeuroDerm located?
NeuroDerm is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.
Who is the current CEO of NeuroDerm?
Ayelet Altman is the current CEO of NeuroDerm.
Is NeuroDerm a funded company?
NeuroDerm is a funded company, having raised a total of $2.5M across 6 funding rounds to date. The company's 1st funding round was a Grant of $400K, raised on May 12, 2006.
What does NeuroDerm do?
NeuroDerm was founded in 2003 in Ness Ziona, Israel, and operates in the biotechnology sector focused on central nervous system disorders. A portfolio of levodopacarbidopa product candidates, including ND0612L for moderate cases, ND0612H for severe cases, and ND0680 for advanced stages, is developed using proprietary reformulation technology to provide continuous dosing. ND801 is also under development for cognitive disorders associated with Parkinsons disease.
Who are the top competitors of NeuroDerm?
NeuroDerm's top competitors include Jazz Pharmaceuticals, Neurocrine and Biohaven Pharmaceutical.
What products or services does NeuroDerm offer?
NeuroDerm offers ND0612.
Who are NeuroDerm's investors?
NeuroDerm has 2 investors. Key investors include The Michael J. Fox Foundation, and Mitsubishi Tanabe Pharma.